Letter

Promoting cost effective prescribing

BMJ 1995; 311 doi: 10.1136/bmj.311.6997.126b (Published 8 July 1995)
Cite this as: BMJ 1995;311:126.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Adrian Towse,
  2. Nicholas Wells
  1. Director Office of Health Economics, London SW1A 2DY
  2. Head of Health Economics Glaxo Pharmaceuticals UK, Uxbridge, Middlesex UB11 1BT

    Cost effectiveness studies may not be cost effective

    EDITOR,--Nick Freemantle and colleagues criticise the NHS for lagging behind Australia and Canada in promoting cost effective prescribing.1 As members of the working group that agreed the British guidance on conducting economic evaluations2 we take issue with their claim that these countries have a preferable approach.

    There is no evidence that Australia and Canada have more cost effective prescribing than the United Kingdom. They have centralised reimbursement lists (federal and provincial, respectively), requiring the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular